 |
|
Bolus Fibrinolytic Therapy in Acute Myocardial Infarction
Joan Llevadot, MD, PhD;
Robert P. Giugliano, MD, SM;
Elliott M. Antman, MD
JAMA. 2001;286:442-449.
Context New bolus fibrinolytics derived from the human tissue-type plasminogen activator (tPA) have emerged as a means of dissolution of occlusive thrombosis associated with acute myocardial infarction.
Objective To review the new bolus fibrinolytic drugs derived from tPA: reteplase, lanoteplase, and tenecteplase.
Data Sources The MEDLINE, EMBASE, and Current Contents databases were searched for articles from 1983 to 2001, using the index terms pharmacokinetics, pharmacodynamics, plasminogen activator, reteplase, lanoteplase, and tenecteplase. Additional data sources included bibliographies of articles identified on MEDLINE, EMBASE, and Current Content, inquiry of experts and pharmaceutical companies, and preliminary data presented at recent national and international cardiology conferences.
Study Selection We selected for review studies that evaluated the pharmacokinetics and pharmacodynamics of reteplase, lanoteplase, and tenecteplase, and assessed the effects of these bolus fibrinolytic drugs on the angiographic and immediate and long-term outcomes of patients. Of 138 articles identified, 38 were analyzed.
Data Extraction Data quality was determined by publication in the peer-reviewed literature or presentation at an official cardiology society–sponsored meeting.
Data Synthesis Tenecteplase and reteplase are comparable with accelerated infusion recombinant tPA in terms of efficacy and safety but more convenient because they are administered by bolus injection. Lanoteplase and heparin bolus plus infusion is as effective as tPA with regard to mortality, but the rate of intracranial hemorrhage is significantly higher.
Conclusion Given the ease of administration and the similar outcomes compared with accelerated infusion recombinant tPA, it is likely that a key component of contemporary reperfusion will include a bolus fibrinolytic.
Author Affiliations: Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
July 25, 2001
JAMA. 2001;286(4):479-480.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Weitz et al.
Chest 2008;133:234S-256S.
ABSTRACT
| FULL TEXT
Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of Human Saphenous Vein, but Not Internal Mammary Artery
Payeli et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:705-710.
ABSTRACT
| FULL TEXT
Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents
Komoriya et al.
Drug Metab. Dispos. 2007;35:469-475.
ABSTRACT
| FULL TEXT
Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2
Carroll et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:736-741.
ABSTRACT
| FULL TEXT
Impact of Prehospital Thrombolysis for Acute Myocardial Infarction on 1-Year Outcome: Results From the French Nationwide USIC 2000 Registry
Danchin et al.
Circulation 2004;110:1909-1915.
ABSTRACT
| FULL TEXT
Evolving strategies in the treatment of acute myocardial infarction in the community hospital setting
McKay
J Am Coll Cardiol 2003;42:642-645.
FULL TEXT
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review
Dundar et al.
QJM 2003;96:103-113.
ABSTRACT
| FULL TEXT
Superiority and equivalence in thrombolytic drugs: an interpretation
WALLEY et al.
QJM 2003;96:155-160.
FULL TEXT
Evaluation of the time saved byprehospital initiation of reteplase forST-elevation myocardial infarction: Results of the early retavase-thrombolysisin myocardial infarction (ER-TIMI) 19 trial
Morrow et al.
J Am Coll Cardiol 2002;40:71-77.
ABSTRACT
| FULL TEXT
Strategy for ensuring a better future for the vessel wall
Corti et al.
Eur Heart J Suppl 2002;4:A31-A41.
ABSTRACT
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2002;7:3-3.
FULL TEXT
Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
Antman et al.
Circulation 2002;105:1642-1649.
ABSTRACT
| FULL TEXT
|
